Sign In   |   Register
News: Publications

Editorial "At the end of the ODYSSEY…what now for PCSK9 inhibition in practice?"

Monday 9 April 2018   (0 Comments)
Share |

In March, the second of the cardiovascular outcomes studies with a PCSK9 inhibitor reported, showing significant clinical benefit in patients with acute coronary syndromes. This commentary discusses these findings in context and considers the implications for clinicians, guideline groups and payers.

"At the end of the ODYSSEY…what now for PCSK9 inhibition in practice?" >>

To the ESC/EAS Consensus Paper on PCSK9 >>

To the ESC/EAS Consensus Paper - update clinical guidance on PCSK9 >>


Membership Software Powered by YourMembership  ::  Legal